Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: Other
Life Threatening? No
Write-up: Information has been received from Sanofi Pasteur MSD [IE-1577272925-2016000290] on 20-JAN-2016. This case was received from the health authority on 15-JAN-2016. Ref IE-HPRA-2015-025523. Initial report was received by the HA on 15-DEC-2015 from a member of the public (patient herself) concerning a 14 year old female patient who experienced hypoaesthesia, headache, dizziness, contusion and immune thrombocytopenic purpura following vaccination with GARDASIL. The patient was not receiving any concomitant medications. The patient had no medical history/concurrent conditions. The patient was vaccinated with three doses of GARDASIL (lot number NM1142D, NM1142D, NN0199O) at a dose of 0.5 ml each time on dates between 20-MAY-2010 and 31-DEC-2010. After the first vaccination on 20-MAY-2010, the patient''s arm was numb and she developed ''constant'' headaches and dizziness. In the weeks after the vaccination, the patient developed ''bleeding and bruising all over the body''. The patient''s GP was contacted and she was sent to the emergency department and subsequently hospitalised. The patient has been attending hospitals and specialist/consultants for the past 6 years and is being treated (unspecified) for idiopathic thrombocytopenic purpura (ITP). The reporter indicated that the patient has ''no understanding where the disorder (ITP) came from'' and that she is at ''high risk of haemorrhaging and prolonged bleeding''. At the time of reporting the patient was not recovered.
Copyright © 2018 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166